Melanoma

P1/2, N=296, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting

This work overturns the longstanding paradigm that ITGB2 is restricted to leukocytes by discovering a tumor cell-intrinsic ITGB2:ICAM-1:Wnt protumorigenic axis as a bona fide cancer therapeutic target in melanoma.

CP-GEP demonstrated good prognostic performance, particularly for patients with pT1b-pT2a melanoma and thus could be considered a noninvasive alternative for a SLNB.

P1, N=322, Active, not recruiting, Sandoz | Recruiting --> Active, not recruiting

P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026

CDKN2A and PCTH1 mutations, frequently detected in melanoma and basal cell carcinoma, respectively, were detected in the second case. The presence of 2 components with distinct immunoprofile yet with some common genetic aberration suggests that basomelanocytic tumors may arise from a common progenitor.

P3, N=186, Recruiting, Philogen S.p.A. | Trial completion date: Jun 2026 --> Dec 2031 | Trial primary completion date: Jun 2024 --> Dec 2027

Patient and family cancer history included other BAP1 -TPDS associated cancers, but only three patients had relatives with meningioma. Our findings indicate a need for routine craniospinal imaging in BAP1 -TPDS patients, and surveillance should include patients without family history of meningioma and patients under the age of 30.

AURKA and AURKB are crucial regulators of tumor progression in RB and UM. Aurora kinase inhibition can be explored as a novel therapeutic strategy.

Myeloperoxidase deficiency effectively reduced Gr-1+ myeloid cell immunosuppression, decreased reactive oxygen species, and diminished extracellular trap formation, thereby eliminating age-dependent differences in tumor growth and immunotherapy response. This work underscores the impact of aging on Gr-1+ myeloid cells on cancer progression and immunotherapy efficacy.

RT-qPCR showed that prognostic genes were up-regulated in human melanoma cells compared to fibroblasts. The identification of ISR-featured prognostic genes and risk score stratification provide new insights into targeting SKCM and enhancing the efficacy of immunotherapy.